stockportfolio.pro
Stocks / AZN vs GILD
AZN vs GILD
AstraZeneca PLC and Gilead Sciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| AstraZeneca PLC (AZN) | Gilead Sciences, Inc. (GILD) | |
|---|---|---|
| Market cap | $281.1B | $154.3B |
| Revenue (latest FY) | $58.74B | $29.44B |
| Net income (latest FY) | $10.22B | $8.51B |
| Revenue growth (5y CAGR) | 9.8% | 3.6% |
| Net margin | 17.4% | 28.9% |
| Return on equity | 21.0% | 37.5% |
| P/E ratio | 27.3 | 16.9 |
| Dividend yield | 1.8% | 2.6% |
| Profitable years (of last 10) | 4 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AZN — free Open GILD — freeFrequently asked questions
Which is bigger, AZN or GILD?
AstraZeneca PLC is larger by market capitalization — $281.1B versus $154.3B.
Which grows faster, AZN or GILD?
Over the last five fiscal years, AstraZeneca PLC grew revenue faster — 9.8%/yr versus 3.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.